Aditxt (ADTX) shares were up over 57% in recent Tuesday trading after its acquisition target, Appili Therapeutics, submitted four new federal funding proposals totaling $117.5 million.
The largest funding proposal seeks $46.3 million to develop a vaccine against invasive fungal infections from the National Institute of Allergy and Infectious Diseases, Appili said.
Aditxt subsidiary, Adivir, is in the process of acquiring Appili, with the transaction expected to close in Q1, the company said.
Trading volume stood at over 87 million shares against a daily average of about 376,000.
Price: 6.90, Change: +2.53, Percent Change: +57.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.